Trials / Completed
CompletedNCT01284608
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 197 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months
Conditions
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2011-01-27
- Last updated
- 2012-12-24
Locations
33 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01284608. Inclusion in this directory is not an endorsement.